HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 12, December 2017 – Skin diseases and allergic reactions       » Gigantic DNA database to be built in Nanjing       » Ineffective baby vaccines by two companies recalled       » Head transplant 'never' to be allowed       » Asia-Pacific, the rising region for cancer vaccine clinical trials       » The hard truth about Eczema      
INSIDE INDUSTRY
California Stem Cell partners on CIRM grant to develop transplantable 3D retinas

California Stem Cell, Inc. (CSC) has initiated a collaborative study with the University of California, Irvine (UCI) aimed to create transplantable 3D retinal tissue. The study, funded by a $4.5 million grant from the California Institute of Regenerative Medicine (CIRM), is a continuation of methods pioneered by CSC scientists in 2010, and will investigate the potential of improving a patient's visual function by transplanting human stem cell-derived three-dimensional (3D) retinal tissue into their retina.

"California Stem Cell looks forward to making a meaningful contribution to work that has the potential to help millions suffering from life-altering retinal diseases."

California Stem Cell, using its specialized cGMP manufacturing facility and regulatory personnel, will differentiate human stem cells into retinal progenitor cells. These cells will then be co-cultured with stem cell-derived retinal pigment epithelium to create a 3D tissue structure suitable for transplantation. Proof of concept in-vivo studies will take place at UCI's Sue & Bill Gross Stem Cell Research Center. Transplants are expected to develop into mature retina, interact with the host tissue, and subsequently improve the vision of retinal degenerative recipients. The study, if successful, could lead to new treatments for incurable retinal diseases such as retinitis pigmentosa and age-related macular degeneration, leading causes of vision loss for people age 50 and older1.

CSC President & CEO Hans Keirstead, Ph.D. will lead the study's work at CSC. "This study establishes a valuable partnership between ourselves and a team of very talented scientists at a university known for its excellence in research," said Keirstead. "California Stem Cell looks forward to making a meaningful contribution to work that has the potential to help millions suffering from life-altering retinal diseases."

The project adds to CSC's pipeline of programs, which also includes two additional human stem cell-based preclinical therapeutic programs for motor neuron disease.

Source: Business Wire

Click here for the complete issue.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases and Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy